CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 119 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $22,150,134 | +136.8% | 744,816 | +43.5% | 0.01% | +133.3% |
Q2 2023 | $9,353,979 | +29.6% | 519,109 | +15.5% | 0.00% | +50.0% |
Q1 2023 | $7,220,275 | +77445.6% | 449,605 | -11.6% | 0.00% | -33.3% |
Q4 2022 | $9,311 | -99.9% | 508,848 | -5.1% | 0.00% | -25.0% |
Q3 2022 | $10,528,000 | +1.9% | 536,070 | -3.2% | 0.00% | 0.0% |
Q2 2022 | $10,329,000 | -3.8% | 553,871 | +13.2% | 0.00% | +33.3% |
Q1 2022 | $10,736,000 | +9.4% | 489,357 | +41.7% | 0.00% | 0.0% |
Q4 2021 | $9,814,000 | +49.7% | 345,444 | +11.0% | 0.00% | +50.0% |
Q3 2021 | $6,554,000 | +87.6% | 311,344 | +68.0% | 0.00% | +100.0% |
Q2 2021 | $3,493,000 | +247.9% | 185,293 | +181.9% | 0.00% | – |
Q1 2021 | $1,004,000 | +197.9% | 65,720 | +175.0% | 0.00% | – |
Q4 2020 | $337,000 | – | 23,895 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |